Global Proliferative Diabetic Retinopathy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Anti-VEGF and Corticosteroids.

By Mode of Administration;

Injectables , Oral and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn145803183 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Proliferative Diabetic Retinopathy Market (USD Million), 2021 - 2031

In the year 2024, the Global Proliferative Diabetic Retinopathy Market was valued at USD 9,953.94 million. The size of this market is expected to increase to USD 15,526.13 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.6%.

The global proliferative diabetic retinopathy (PDR) market is witnessing significant growth, fueled by the increasing prevalence of diabetes worldwide and the subsequent rise in diabetic retinopathy cases. Proliferative diabetic retinopathy, a severe complication of diabetes, occurs when abnormal blood vessels grow on the retina, leading to vision impairment and, if left untreated, irreversible blindness. With the escalating diabetes epidemic, particularly in developing countries, the incidence of PDR is expected to rise, driving demand for effective treatment options and driving growth in the global market for PDR therapeutics and devices.

Advancements in medical technology and treatment modalities are playing a pivotal role in shaping the landscape of the proliferative diabetic retinopathy market. Innovations such as anti-vascular endothelial growth factor (anti-VEGF) injections, laser photocoagulation, and vitrectomy surgery have revolutionized the management of PDR, offering improved outcomes and preserving vision in patients with advanced disease. Additionally, the development of novel drug delivery systems and combination therapies holds promise for enhancing treatment efficacy and reducing the burden of frequent injections or surgical interventions for patients with PDR.

However, the proliferative diabetic retinopathy market faces challenges such as limited access to healthcare services, particularly in underserved regions, and the high cost of PDR treatments and devices. Economic factors, including healthcare expenditure and reimbursement policies, also influence market dynamics and patient access to advanced PDR therapies. Despite these challenges, the growing awareness of diabetic retinopathy screening and early intervention, coupled with ongoing research and development efforts aimed at improving treatment outcomes and reducing treatment burden, are expected to drive continued growth in the global proliferative diabetic retinopathy market in the coming years.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Mode of Administration
    3. Market Snapshot, By Region
  4. Global Proliferative Diabetic Retinopathy Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Diabetes
        2. Advancements in Treatment Modalities
        3. Growing Awareness of Diabetic Retinopathy Screening
      2. Restraints
        1. Limited Access to Healthcare Services
        2. High Cost of Treatments and Devices
        3. Economic Factors and Reimbursement Policies
      3. Opportunities
        1. Development of Novel Drug Delivery Systems
        2. Expansion of Screening Programs
        3. Ongoing Research and Development Efforts
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Proliferative Diabetic Retinopathy Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Anti-VEGF
      2. Corticosteroids
    2. Global Proliferative Diabetic Retinopathy Market, By Mode of Administration, 2021 - 2031 (USD Million)
      1. Injectables
      2. Oral
      3. Others
    3. Global Proliferative Diabetic Retinopathy Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novartis AG
      2. Regeneron Pharmaceuticals, Inc.
      3. Roche Holding AG
      4. Bayer AG
      5. Allergan plc
      6. Genentech, Inc. (a subsidiary of Roche)
      7. Alimera Sciences, Inc.
      8. Bausch Health Companies Inc.
      9. Santen Pharmaceutical Co., Ltd.
      10. Graybug Vision, Inc.
  7. Analyst Views
  8. Future Outlook of the Market